Together We Can Make “Rare” More Familiar

According to NORD, There are more than 7,000 known rare diseases, and the number of Americans living with a rare disease is estimated at 25-30 million. Beyond the symptoms of their disease, patients face a challenging journey that may include finding a diagnosis, hoping and advocating for a treatment, and navigating roadblocks to equitable access to healthcare. 

Through our recently announced collaboration with Stoke Therapeutics, we are pursuing new possibilities for the treatment of rare, neurodevelopmental diseases, including SYNGAP1 syndrome, a severe neurological disorder evident in early childhood and associated with developmental delays, motor function loss, and other comorbidities that impact quality of life for patients and their families.

Our clinical development of a treatment for Rett syndrome – a rare, debilitating neurological disorder that occurs primarily in females following apparently normal development for the first 6-18 months of life – will be submitted in a New Drug Application (NDA) to the FDA this year. It could be the first approved treatment for the estimated 6,000-9,000 Rett patients in the U.S. and Acadia’s first commercial entry into the rare disease space

Advocacy is vital to supporting these rare disease communities both on Rare Disease Day, which is February 28, and throughout the year. Acadia has joined with the International Rett Syndrome Foundation to support educational webinars and introduced the Rett Parents Council to reach out to the Rett community and learn first-hand their challenges and needs.

Join us in supporting the rare disease community on Rare Disease Day each year by sharing your photos or story and using #rarediseaseday on Twitter. On this day, we also light up our Acadia buildings with the colors of Rare Disease Day. You can Light Up for Rare, too, and shine a beacon from your home or office.

Together, we can make “rare” more familiar, changing and improving the lives of every person in this community.